Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Summary

This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.

Eligibility

Inclusion Criteria:

* Patient aged 18 years or more
* Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
* Patient with localized endometrial cancer, presenting:

  * A high-grade endometrioid histological type and/or
  * P53 mutation and/or
  * a non-endometrioid histological type regardless of P53 status.
* Patient affiliated to a social security scheme
* Information and signature of informed consent prior to any specific study procedure

Exclusion Criteria:

* Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
* Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Conditions2

Browse More Trials